{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Duchenne&page=2",
    "query": {
      "condition": "Duchenne",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Duchenne&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T01:34:40.381Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02760264",
      "title": "A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "Vamorolone 0.25 mg/kg/day",
          "type": "DRUG"
        },
        {
          "name": "Vamorolone 0.75 mg/kg/day",
          "type": "DRUG"
        },
        {
          "name": "Vamorolone 2.0 mg/kg/day",
          "type": "DRUG"
        },
        {
          "name": "Vamorolone 6.0 mg/kg/day",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ReveraGen BioPharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "6 Years",
        "sex": "MALE",
        "summary": "4 Years to 6 Years · Male only"
      },
      "enrollment_count": 48,
      "start_date": "2016-06",
      "completion_date": "2018-05-01",
      "has_results": true,
      "last_update_posted_date": "2019-01-02",
      "last_synced_at": "2026-07-24T01:34:40.381Z",
      "location_count": 6,
      "location_summary": "Davis, California • Gainesville, Florida • Orlando, Florida + 3 more",
      "locations": [
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02760264"
    },
    {
      "nct_id": "NCT01388764",
      "title": "Safety, Tolerability and Effects of L-Arginine in Boys With Dystrophinopathy on Corticosteroids",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dystrophinopathy",
        "Duchenne Muscular Dystrophy",
        "Becker's Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "L-arginine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "11 Years",
        "sex": "MALE",
        "summary": "7 Years to 11 Years · Male only"
      },
      "enrollment_count": 7,
      "start_date": "2012-01",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2012-07-03",
      "last_synced_at": "2026-07-24T01:34:40.381Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01388764"
    },
    {
      "nct_id": "NCT03907072",
      "title": "Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "WVE-210201 (suvodirsen)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wave Life Sciences USA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "12 Years",
        "sex": "MALE",
        "summary": "5 Years to 12 Years · Male only"
      },
      "enrollment_count": 6,
      "start_date": "2019-09-04",
      "completion_date": "2020-01-09",
      "has_results": true,
      "last_update_posted_date": "2021-05-20",
      "last_synced_at": "2026-07-24T01:34:40.381Z",
      "location_count": 6,
      "location_summary": "New Haven, Connecticut • Atlanta, Georgia • Kansas City, Kansas + 3 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03907072"
    },
    {
      "nct_id": "NCT03836300",
      "title": "Parent and Infant Inter(X)Action Intervention (PIXI)",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Fragile X Syndrome",
        "Angelman Syndrome",
        "Prader-Willi Syndrome",
        "Dup15Q Syndrome",
        "Duchenne Muscular Dystrophy",
        "Phelan-McDermid Syndrome",
        "Rett Syndrome",
        "Smith Magenis Syndrome",
        "Williams Syndrome",
        "Turner Syndrome",
        "Klinefelter Syndrome",
        "Chromosome 22q11.2 Deletion Syndrome",
        "Tuberous Sclerosis",
        "Down Syndrome"
      ],
      "interventions": [
        {
          "name": "Parent-Infant Inter(X)action Intervention (PIXI)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "RTI International",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "Up to 99 Years"
      },
      "enrollment_count": 120,
      "start_date": "2018-11-30",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-07-24T01:34:40.381Z",
      "location_count": 1,
      "location_summary": "Research Triangle Park, North Carolina",
      "locations": [
        {
          "city": "Research Triangle Park",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03836300"
    },
    {
      "nct_id": "NCT01847573",
      "title": "Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "HT-100",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Processa Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "20 Years",
        "sex": "MALE",
        "summary": "6 Years to 20 Years · Male only"
      },
      "enrollment_count": 17,
      "start_date": "2013-05",
      "completion_date": "2016-03-30",
      "has_results": false,
      "last_update_posted_date": "2020-09-03",
      "last_synced_at": "2026-07-24T01:34:40.381Z",
      "location_count": 5,
      "location_summary": "Sacramento, California • Baltimore, Maryland • St Louis, Missouri + 2 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01847573"
    },
    {
      "nct_id": "NCT02525302",
      "title": "HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "HT-100",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Akashi Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "20 Years",
        "sex": "MALE",
        "summary": "6 Years to 20 Years · Male only"
      },
      "enrollment_count": 10,
      "start_date": "2015-05",
      "completion_date": "2016-12-30",
      "has_results": false,
      "last_update_posted_date": "2019-03-12",
      "last_synced_at": "2026-07-24T01:34:40.381Z",
      "location_count": 5,
      "location_summary": "Sacramento, California • Baltimore, Maryland • St Louis, Missouri + 2 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02525302"
    },
    {
      "nct_id": "NCT00451074",
      "title": "Six Month Study of Gentamicin in Duchenne Muscular Dystrophy With Stop Codons",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "Gentamicin infusions twice a week for six months",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nationwide Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "20 Years",
        "sex": "MALE",
        "summary": "5 Years to 20 Years · Male only"
      },
      "enrollment_count": 12,
      "start_date": "2007-03",
      "completion_date": "2009-07",
      "has_results": false,
      "last_update_posted_date": "2012-03-23",
      "last_synced_at": "2026-07-24T01:34:40.381Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Kansas City, Kansas • Columbus, Ohio",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00451074"
    },
    {
      "nct_id": "NCT02530905",
      "title": "Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "SRP-4045",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sarepta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "21 Years",
        "sex": "MALE",
        "summary": "7 Years to 21 Years · Male only"
      },
      "enrollment_count": 12,
      "start_date": "2015-10-08",
      "completion_date": "2018-10-03",
      "has_results": true,
      "last_update_posted_date": "2021-05-17",
      "last_synced_at": "2026-07-24T01:34:40.381Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Chicago, Illinois • Baltimore, Maryland",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02530905"
    },
    {
      "nct_id": "NCT03936894",
      "title": "Single Escalating Dose Pilot Trial of Canakinumab (ILARIS®) in Duchenne Muscular Dystrophy",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "Canakinumab Injection [Ilaris]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's National Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "2 Years and older · Male only"
      },
      "enrollment_count": 3,
      "start_date": "2019-05-01",
      "completion_date": "2024-04",
      "has_results": false,
      "last_update_posted_date": "2023-09-21",
      "last_synced_at": "2026-07-24T01:34:40.381Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03936894"
    },
    {
      "nct_id": "NCT07609394",
      "title": "Duchenne Electronic Health Record Study",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Duchenne Muscular Dystrophy (DMD)",
        "Becker Muscular Dystrophy",
        "Dystrophinopathy",
        "Dystrophinopathy Symptomatic Female Carrier"
      ],
      "interventions": [
        {
          "name": "Observational study with patients who may be treated with various disease-modifying therapies",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "The Duchenne Registry",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 2500,
      "start_date": "2022-12-01",
      "completion_date": "2072-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-07-24T01:34:40.381Z",
      "location_count": 10,
      "location_summary": "Little Rock, Arkansas • Sacramento, California • Aurora, Colorado + 6 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07609394"
    }
  ]
}